Cell and Gene Therapy Orchestration Solutions
Description
This IDC Perspective frames CGT’s “batch size of one” reality and positions orchestration as the workflow integration/control layer needed to scale autologous patient-product-patient operations. It spotlights the critical challenges, ensuring a secure COI/COC across a multi-enterprise network, constraint-heavy scheduling, interoperability across MES/LIMS/QMS/ERP and partner systems, and GxP-ready governance/auditability. It identifies specific use cases where AI can add value, along with the challenges. It provides practical buyer guidance and KPIs for CGT orchestration solutions.“The future of precision medicine runs on CGT orchestration solutions: smart execution layers that connect manufacturing, QC, and cryologistics. They digitize COI/COC across the patient-product life cycle, compress vein-to-vein timelines, and optimize clinical outcomes,” said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC.
Table of Contents
8 Pages
Executive snapshot
Key takeaways
Recommended actions
Situation overview
CGT orchestration solutions — key drivers
Orchestrating the future of CGT manufacturing and supply chain
Key challenges that orchestration must solve
Embedding the AI narrative in CGT orchestration solutions
The challenges in leveraging AI in CGT orchestration solutions
Conclusion
Advice for the technology buyer
Learn more
Related research
Synopsis
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



